Ovarian Cancer

Rubraca Significantly Improves Survival Ovarian Cancer (01-18-2018)

CancerConnect News: According to the results of a recently published clinical trail the novel precision cancer medicine Rubraca® (rucaparib) improves the outcomes of individuals with advanced ovarian cancer. About Rubraca® Rubraca® is an oral taken... Continue Reading

Ovarian Cancer: Doctors at Sloan Kettering Explore Immunotherapy (01-16-2018)

CancerConnect News:  All gynecologic cancers are challenging to treat. They can be hard to find and are usually diagnosed when they are advanced. Although these cancers can be held at bay with surgery or chemotherapy, they often return and become difficult... Continue Reading

Pass it On: It’s National Ovarian Cancer Awareness Month (09-11-2017)

In 2016, the American Cancer Association estimates that 22,280 women will be diagnosed with ovarian cancer, and 14,240 women will die from the disease. The incidence of ovarian cancer has decreased slightly in the past decade or so, though the reason... Continue Reading

Ovarian Cancer Clinical Trials: What, Where, Why (07-5-2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

Endometriosis Patients are at Increased Risk for Ovarian Cancer, Study Confirms (05-3-2017)

A large study based on the Nurses’ Health confirms that endometriosis is associated with increased risk of ovarian cancer.  Moreover, it further clarifies that this condition is not linked to a greater risk for endometrial cancer. Many women with endometriosis... Continue Reading

Recruitment Begins for World’s First Ovarian Cancer Vaccine Trial (04-25-2017)

UConn Health is beginning to recruit patients for the world’s first personalized genomics-driven ovarian cancer vaccine clinical trial. The goal: to prevent an often deadly relapse of the disease in women diagnosed at advanced stages. The pioneering... Continue Reading

Niraparib Approved for Ovarian Cancer Maintenance Treatment (04-3-2017)

Zejula (Niraparib) has been approved by the US Food and Drug Administration (FDA) for use as maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal who are in complete or partial response to platinum-based... Continue Reading

New Ovarian Cancer Immunotherapy Study Poses Question: Can Microbiome Influence Treatment Response? (03-6-2017)

A clinical study with Keytruda (pembrolizumab) in a novel untried combination is the first ovarian cancer clinical trial to incorporate gut flora analysis.  Dr. Emese Zsiros, the study’s Principal Investigator, explains a new, unique clinical trial... Continue Reading

Chemo-brain Among Women with Breast Cancer is Very Common (02-28-2017)

The largest study to date of a condition known as “chemo-brain” shows that women with breast cancer report it’s a substantial problem after chemotherapy for as long as six months after treatment, according to investigators at the Wilmot Cancer Institute. Scientists... Continue Reading

Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer (12-20-2016)

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rubraca™ (rucaparib) for the treatment of women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a BRCA gene mutation. Each... Continue Reading

Next Page »